Securities Code: 002399 Securities Abbreviation: Hepalink Announcement No.: 2026-002
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Resolution Announcement of the 20th Meeting of the 6th Board of Directors
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or material omissions.
I. Convening of the Board Meeting
The notice and proposals for the 20th meeting of the 6th Board of Directors (hereinafter referred to as the "Meeting") of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") were sent via email on March 16, 2026. The Meeting was held on March 30, 2026, at 2:00 PM at the conference room at No. 21, Langshan Road, Songpingshan, Nanshan District, Shenzhen, through a combination of on-site and teleconference methods. A total of 7 directors were eligible to vote, and all 7 directors actually participated in the vote. Mr. Zhang Ping participated in the vote via teleconference. Senior management personnel of the Company attended the meeting as non-voting participants. The meeting was presided over by Mr. Li Li, Chairman of the Board. The notice, convening, and the number of directors participating in the vote all comply with relevant laws and regulations and the Company's Articles of Association.
II. Deliberation of the Board Meeting
After careful deliberation by the attending directors, the following proposals were approved: